NiveshIQNiveshIQ
NSE: ABBOTINDIA  ·  Healthcare

Abbott India Ltd.

₹27,745.00▼ ₹160.00 (-0.57%)
Volume: 9,930Day Range: ₹27,600.00 – ₹28,090.0052W Range: ₹25,150.00 – ₹35,310.00
Price Chart  ·  Daily closes
1Y 6M 3M 1M 1W 1D
⚡ Intelligence Signals 5 active
🟢 Bullish Earnings Catalyst 📊 RS Laggard (5D) 🔄 Sector Sweep ⚡ Signals Aligned 📉 Pullback

NiveshIQ has detected 5 active signals on ABBOTINDIA. Sign up free to see what each signal means and how it affects the stock.

Unlock signals — free
Expected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74 / 100

About Abbott India Ltd.

Abbott India Limited is a leading pharmaceutical company in India, offering a diverse portfolio of products across gastroenterology, women's health, metabolic, central nervous system, vaccines, and multispecialty segments. The company's key revenue drivers include its strong presence in the Indian market, a wide range of products, and a robust distribution network. Recently, Abbott India has seen a significant jump in its sales and profit outlook, with its enterprise value to revenue forward ratio indicating a strong growth potential. The company's price to sales and price to earnings forward ratios also suggest a competitive position in the market. With a revenue of ₹6929 Cr and net income of ₹1552 Cr, Abbott India is well-positioned for growth. The company's growth outlook is further sup

Financial Highlights

MetricFY24FY25FY26
Revenue₹5,849 Cr +9.30%₹6,410 Cr +9.60%₹6,929 Cr +8.10%
EBITDA Margin24.86%26.44%28.40%
Net Profit₹1,201 Cr +26.60%₹1,415 Cr +17.80%₹1,552 Cr +9.70%
EPS₹565.30₹665.63₹730.39

Annual figures in Indian Rupees (Crores). Source: BSE filings.

Analyst ConsensusConsensus target ₹32,652.38  |  Buy 6 · Hold 1 · Sell 1Sign in to see →

Recent News

🔒
+ 3 more stories about Abbott India Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instant

Strategic Outlook

Recent corporate activity underscores the company's focus on product launches, approvals, and therapy-mix improvement, w...

FY26 (last completed FY): revenue ₹6, 929 Cr, PAT ₹1, 552 Cr, EBITDA margin 28.4%, EPS ₹730.39. Year-on-year: revenue Yo...

🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instant

Everything you unlock with a free account

Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for ABBOTINDIA
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track ABBOTINDIA alongside your other holdings
Unlock full ABBOTINDIA research — free
No credit card  ·  No trial  ·  Always free to start

Frequently Asked Questions

What AI signals does NiveshIQ provide for Abbott India Ltd.?

NiveshIQ detects active intelligence signals for Abbott India Ltd. (ABBOTINDIA) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.

What are the key financials for Abbott India Ltd.?

Abbott India Ltd. operates in the Healthcare sector with a market capitalisation of ₹5,895,618.6L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.

Does NiveshIQ provide investment advice?

No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.

Viewing preview of Abbott India Ltd. — 5 active signals detected Unlock full analysis — free